Diabetes-specific formula with standard of care improves glycemic control, body composition, and cardiometabolic risk factors in overweight and obese adults with type 2 diabetes: results from a randomized controlled trial.

Autor:	Tey SL; Abbott Nutrition Research and Development, Asia-Pacific Centre, Singapore, Singapore., Chee WSS; Department of Nutrition and Dietetics, International Medical University, Kuala Lumpur, Malaysia., Deerochanawong C; Department of Medicine, Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok, Thailand., Berde Y; Biostatistics and Statistical Programming, Cognizant Technology Solutions, Mumbai, India., Lim LL; Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia., Boonyavarakul A; Department of Medicine, Phramongkutklao Hospital, Bangkok, Thailand., Wakefield B; Abbott Nutrition Research and Development, Columbus, OH, United States., Baggs G; Abbott Nutrition Research and Development, Columbus, OH, United States., Huynh DTT; Abbott Nutrition Research and Development, Asia-Pacific Centre, Singapore, Singapore.
Jazyk:	angličtina
Zdroj:	Frontiers in nutrition [Front Nutr] 2024 Jul 15; Vol. 11, pp. 1400580. Date of Electronic Publication: 2024 Jul 15 (Print Publication: 2024).
DOI:	10.3389/fnut.2024.1400580
Abstrakt:	Background and Aims: Medical nutrition therapy is important for diabetes management. This randomized controlled trial investigated the effects of a diabetes-specific formula (DSF) on glycemic control and cardiometabolic risk factors in adults with type 2 diabetes (T2D). Methods: Participants ( n  = 235) were randomized to either DSF with standard of care (SOC) (DSF group; n  = 117) or SOC only (control group; n  = 118). The DSF group consumed one or two DSF servings daily as meal replacement or partial meal replacement. The assessments were done at baseline, on day 45, and on day 90. Results: There were significant reductions in glycated hemoglobin (-0.44% vs. -0.26%, p =  0.015, at day 45; -0.50% vs. -0.21%, p =  0.002, at day 90) and fasting blood glucose (-0.14 mmol/L vs. +0.32 mmol/L, p =  0.036, at day 90), as well as twofold greater weight loss (-1.30 kg vs. -0.61 kg, p   < 0.001, at day 45; -1.74 kg vs. -0.76 kg, p  < 0.001, at day 90) in the DSF group compared with the control group. The decrease in percent body fat and increase in percent fat-free mass at day 90 in the DSF group were almost twice that of the control group (1.44% vs. 0.79%, p =  0.047). In addition, the percent change in visceral adipose tissue at day 90 in the DSF group was several-fold lower than in the control group (-6.52% vs. -0.95%, p  < 0.001). The DSF group also showed smaller waist and hip circumferences, and lower diastolic blood pressure than the control group (all overall p  ≤ 0.045). Conclusion: DSF with SOC yielded significantly greater improvements than only SOC in glycemic control, body composition, and cardiometabolic risk factors in adults with T2D. Competing Interests: SLT, GB, BW, and DTTH are employees of Abbott Nutrition. YB was an employee of Cognizant Technology Solutions, a contract research organization that provides statistical services to Abbott Nutrition and has no competing interests. WSSC reports receiving research grants and honoraria for consultancy from Abbott Nutrition and honoraria for consultancy or speaking engagements from Novo Nordisk, Merck, Boehringer Ingelheim, and AstraZeneca. CD reports receiving research grants and honoraria for consultancy and speaking engagements from Abbott. L-LL reports receiving grants and/or honoraria for consultancy or giving lectures from Abbott, AstraZeneca, Boehringer Ingelheim, Novartis, Novo Nordisk, Roche, Sanofi, Servier, and Zuellig Pharma. AB reports receiving research grant and honoraria for consultancy and speaking from Abbott, Novartis, and Novo Nordisk, as well as receiving honoraria for consultancy or giving lectures from Abbott, AstraZeneca, Boehringer Ingelheim, Novartis, Novo Nordisk, Sanofi, Servier, Bayer, and Zuellig Pharma. The funders were involved in the design of the study; in the collection, analyses, or interpretation of data; and in the writing of the manuscript. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. (Copyright © 2024 Tey, Chee, Deerochanawong, Berde, Lim, Boonyavarakul, Wakefield, Baggs and Huynh.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu